Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
---|---|---|---|---|---|---|
LYEL | Lyell Immunopharma, Inc. | Chief Business Officer | $114K | Feb 9, 2024 | ||
MYOV | Myovant Sciences Ltd. | General Counsel & Corp. Secy. | Mar 10, 2023 |
Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
---|